Skip to main content
Log in

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease modifying antirheumatic drugs in quite a number of patients. Tumor necrosis factor inhibitors have demonstrated to be of value in reducing AS disease activity in clinical trials. The efficacy and safety of both etanercept and infliximab in patients with ankylosing spondylitis were compared in a 2-year open label randomised study. Our results are consistent with a significant more rapid clinical improvement in the infliximab treated group. Treatment with both etanercept and infliximab at the end of the study was effective, safe, and well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Khan MA (2002) Update on spondyloarthropathies. Ann Intern Med 135:896–907

    Google Scholar 

  2. Zochling J, van der Heijde D, Dougados M et al (2006) Current evidence for the management of ankylosing spondylitis: systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65:423–432

    Article  CAS  PubMed  Google Scholar 

  3. Rudwaleit M, Hohler T (2001) Cytokine gene polymorphisms relevant for the spondyloarthropathies. Curr Opin Rheumatol 13:250–254

    Article  CAS  PubMed  Google Scholar 

  4. Davis JC, van der Heijde DM, Braun J et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346–352

    Article  CAS  PubMed  Google Scholar 

  5. Brandt J, Khariouzov A, Listing J, Haibel H et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667–1675

    Article  CAS  PubMed  Google Scholar 

  6. Davis JC, van der Heijde DM, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum 48:3230–3236

    Article  CAS  PubMed  Google Scholar 

  7. Calin A, Dijkmans BAC, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594–1600

    Article  CAS  PubMed  Google Scholar 

  8. Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342–348

    Article  CAS  PubMed  Google Scholar 

  9. Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193

    Article  CAS  PubMed  Google Scholar 

  10. Braun J, Brandt J, Listing J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64:229–234

    Article  CAS  PubMed  Google Scholar 

  11. van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 52:582–591

    Article  PubMed  Google Scholar 

  12. Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64:1568–1575

    Article  CAS  PubMed  Google Scholar 

  13. Braun J, Brandt J, Listing J et al (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224–2233

    Article  CAS  PubMed  Google Scholar 

  14. Braun J, Landewé R, Hermann KGA et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646–1652

    Article  CAS  PubMed  Google Scholar 

  15. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE (2005) The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34:819–836

    Article  CAS  PubMed  Google Scholar 

  16. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 27:361–368

    Article  PubMed  Google Scholar 

  17. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M (2001) Ankylosing Spondylitis Assessment Group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:1876–1886

    Article  CAS  PubMed  Google Scholar 

  18. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index. J Rheumatol 21:1694–1698

    CAS  PubMed  Google Scholar 

  19. Fernández-Sueiro JL, Willisch A, Pértega-Díaz S et al (2009) Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 61(3):386–392

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Giovanni Triolo.

Additional information

A. R. Giardina and A. Ferrante contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Giardina, A.R., Ferrante, A., Ciccia, F. et al. A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 30, 1437–1440 (2010). https://doi.org/10.1007/s00296-009-1157-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-1157-3

Keywords

Navigation